Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 04, 2016 07:01 ET | Source: Summit Therapeutics plc

Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement with Sarepta

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Summit Therapeutics plc ("Summit" or the...
October 04, 2016 07:01 ET | Source: Summit Therapeutics PLC

Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy

OXFORD, United Kingdom, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
October 04, 2016 07:00 ET | Source: Summit Therapeutics plc

Sarepta Therapeutics and Summit Enter into Exclusive License and Collaboration Agreement

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Sarepta Therapeutics and Summit Enter...
October 04, 2016 07:00 ET | Source: Summit Therapeutics PLC; Sarepta Therapeutics

Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy

Sarepta and Summit collaborate to advance the development of novel therapies for patients with Duchenne muscular dystrophySummit receives $40 million upfront, with potential future ezutromid-related...
September 28, 2016 04:45 ET | Source: Summit Therapeutics plc

Summit Therapeutics plc : Holding(s) in Company

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} TR-1:...
September 27, 2016 07:00 ET | Source: Summit Therapeutics plc

Summit Received Rare Pediatric Disease Designation from US FDA for Ezutromid in Treatment of DMD

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Summit Therapeutics plc ("Summit" or "the...
September 27, 2016 07:00 ET | Source: Summit Therapeutics PLC

Summit Receives Rare Pediatric Disease Designation From US FDA for Ezutromid in Treatment of Duchenne Muscular Dystrophy

OXFORD, United Kingdom, Sept. 27, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
September 26, 2016 07:00 ET | Source: Summit Therapeutics plc

Summit Receives Fast Track Designation from US FDA for Ezutromid in the Treatment of DMD

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Summit Therapeutics plc ("Summit" or "the...
September 26, 2016 07:00 ET | Source: Summit Therapeutics PLC

Summit Receives Fast Track Designation From US FDA for Ezutromid in the Treatment of Duchenne Muscular Dystrophy

OXFORD, United Kingdom, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
September 12, 2016 07:00 ET | Source: Summit Therapeutics PLC

Summit Launches Online Resource on Utrophin Modulation for the Duchenne Muscular Dystrophy Community

OXFORD, United Kingdom, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...